Digital Health/Clinical Trials
Information Mediary Corp. (IMC)
We build tools and technologies to provide medication adherence insights, cold chain and smart drug logistics
?According to one estimate,?50% of US clinical trial participants?come from 1-2% of all ZIP codes. Members of Black, Latino and Asian communities are?massively underrepresented?in clinical trials. Furthermore, patients from all communities are impacted by an awareness gap when it comes to clinical trials. According to the latest National Cancer Institute Health Information National Trends survey,?only 11.3% of respondents?indicated that they knew “a lot” about clinical trials. This awareness and access gap comes with consequences. Without a sufficiently diverse pool of trial participants, there is a perennial risk that new drugs and therapies might underperform for underrepresented populations.HITLAB Invites Clinical Trial Enthusiasts To Participate in a Survey on use of Digital Technologies in Clinical Trials
HITLAB?is conducting research on the use of digital technologies, including remote monitoring, for decentralized clinical trial (DCT) designs and is asking for trial specialists to complete a brief survey:?Clinical Trial Enthusiast Survey.?After?receiving a representative set of responses, our Chair, Dr. Stan Kachnowski, will publish a paper on our findings. The survey is confidential and used for research.
A pioneering behavioural diagnostic tool developed by Kingston University, London and healthcare technology company Observia to help patients take their medication as prescribed is the first holistic model in the world to accurately predict hospital admissions and readmissions in people living with Type 2 Diabetes, according to a new study.
领英推荐
The pharmaceutical industry is facing global challenges, resulting in a constant need for change and adaptation to be efficient and successful. Within the past five years the industry dealt with the impact of Brexit, continuously changing regulations, the COVID-19 pandemic, and geopolitical conflicts to name a few. These companies had to adapt their global supply chain strategy to ensure that all active patients were receiving continuous treatment, regardless of the surrounding turmoil. On top of this unforeseen unpredictability, the pharmaceutical companies are switching to more biotechnology-driven drugs which decreases the already tight expiry constraints.?
?Expanded access, also known as compassionate use, allows certain patients with serious disease to access experimental drugs outside of the clinical trial setting. The 21st?Century Cures Act, which became US law in December 2016, requires companies that offer expanded access to make their policy for evaluating and responding to requests “public and readily available.” The law does not require companies to offer expanded access, but they must also make this position publicly visible.
?
Rose Blackburne, MD, MBA, Vice President, Global Head, General Medicine, PPD Clinical Research, Thermo Fisher and Margarita Nunez, MD, Principal Investigator, Synexus NY / Accelerated Enrollment Solutions New York discuss their panel at the recent Health Equity in Clinical Trials Congress in Boston last month; share insights into how diversity can be improved at the site and CRO; and the hope that clinical trial awareness and diversity can be discussed with all levels of stakeholders in healthcare to improve drug development worldwide.